Biosimilars : Design and Analysis of Follow-on Biologics.
As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator's biologic products. But scientific ch...
Saved in:
Main Author: | |
---|---|
Format: | Electronic eBook |
Language: | English |
Published: |
Hoboken :
CRC Press,
2013.
|
Series: | Chapman & Hall/CRC biostatistics series.
|
Subjects: | |
Online Access: |
Full text (WIT users only) |